Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £451,250 and Director’s Dealing
Hemogenyx Pharmaceuticals (LSE:HEMO) has successfully raised £451,250 through a placing of 250,000 new ordinary shares at 180.5p per share. The shares were initially allotted to CEO Vladislav Sandler, who will direct their issue to an institution for immediate sale to an identified purchaser. The purchaser will receive one-for-one warrants exercisable for 36 months at 270 pence.
The funds will support the continuation of Phase I clinical trials for the company's HG-CT-1 therapy, targeting relapsed/refractory acute myeloid leukemia in adults. Two patients have already been infused with the treatment. Upon admission of the new shares, expected around May 14, 2025, the total number of issued shares will be 4,343,539.
Hemogenyx Pharmaceuticals (LSE:HEMO) ha raccolto con successo £451.250 attraverso un collocamento di 250.000 nuove azioni ordinarie al prezzo di 180,5p per azione. Le azioni sono state inizialmente assegnate al CEO Vladislav Sandler, che ne curerà l'emissione a favore di un istituto per la vendita immediata a un acquirente identificato. L'acquirente riceverà warrant uno a uno esercitabili per 36 mesi a 270 pence.
I fondi serviranno a sostenere la prosecuzione delle sperimentazioni cliniche di Fase I per la terapia HG-CT-1 dell'azienda, rivolta alla leucemia mieloide acuta recidivante/refrattaria negli adulti. Due pazienti sono già stati trattati con questa terapia. All'ammissione delle nuove azioni, prevista intorno al 14 maggio 2025, il numero totale di azioni emesse sarà di 4.343.539.
Hemogenyx Pharmaceuticals (LSE:HEMO) ha recaudado con éxito £451,250 mediante una colocación de 250,000 nuevas acciones ordinarias a 180,5p por acción. Las acciones fueron asignadas inicialmente al CEO Vladislav Sandler, quien dirigirá su emisión a una institución para su venta inmediata a un comprador identificado. El comprador recibirá warrants uno a uno ejercitables durante 36 meses a 270 peniques.
Los fondos apoyarán la continuación de los ensayos clínicos de Fase I para la terapia HG-CT-1 de la compañía, dirigida a la leucemia mieloide aguda en recaída/refractaria en adultos. Dos pacientes ya han sido tratados con este tratamiento. Tras la admisión de las nuevas acciones, prevista alrededor del 14 de mayo de 2025, el número total de acciones emitidas será de 4,343,539.
Hemogenyx Pharmaceuticals (LSE:HEMO)는 250,000주의 신규 보통주를 주당 180.5펜스에 배정하여 £451,250를 성공적으로 조달했습니다. 해당 주식은 처음에 CEO 블라디슬라브 샌들러에게 배정되었으며, 그는 이를 기관에 발행하여 확인된 구매자에게 즉시 판매할 예정입니다. 구매자는 36개월 동안 행사 가능한 1대1 워런트를 270펜스에 받게 됩니다.
이번 자금은 성인 재발/불응성 급성 골수성 백혈병을 대상으로 하는 회사의 HG-CT-1 치료제 1상 임상 시험 지속을 지원할 것입니다. 이미 두 명의 환자가 치료를 받았습니다. 신규 주식 상장은 2025년 5월 14일경으로 예상되며, 총 발행 주식 수는 4,343,539주가 됩니다.
Hemogenyx Pharmaceuticals (LSE:HEMO) a réussi à lever 451 250 £ grâce à un placement de 250 000 nouvelles actions ordinaires au prix de 180,5 pence par action. Les actions ont été initialement attribuées au PDG Vladislav Sandler, qui dirigera leur émission vers une institution pour une vente immédiate à un acheteur identifié. L'acheteur recevra des bons de souscription un pour un, exerçables pendant 36 mois au prix de 270 pence.
Les fonds permettront de soutenir la poursuite des essais cliniques de phase I pour la thérapie HG-CT-1 de la société, ciblant la leucémie myéloïde aiguë en rechute/réfractaire chez l'adulte. Deux patients ont déjà été traités avec ce traitement. À l'admission des nouvelles actions, prévue vers le 14 mai 2025, le nombre total d'actions émises sera de 4 343 539.
Hemogenyx Pharmaceuticals (LSE:HEMO) hat erfolgreich £451.250 durch die Platzierung von 250.000 neuen Stammaktien zu je 180,5 Pence pro Aktie aufgenommen. Die Aktien wurden zunächst dem CEO Vladislav Sandler zugeteilt, der deren Ausgabe an eine Institution weiterleiten wird, um sie sofort an einen identifizierten Käufer zu verkaufen. Der Käufer erhält Ein-zu-eins-Warrants, die 36 Monate lang zu 270 Pence ausgeübt werden können.
Die Mittel werden die Fortführung der Phase-I-Studien für die HG-CT-1-Therapie des Unternehmens unterstützen, die sich an erwachsene Patienten mit rezidivierender/refraktärer akuter myeloischer Leukämie richtet. Zwei Patienten wurden bereits mit der Behandlung versorgt. Nach der Zulassung der neuen Aktien, voraussichtlich um den 14. Mai 2025, wird die Gesamtzahl der ausgegebenen Aktien 4.343.539 betragen.
- Fundraising completed at market price with no discount, indicating investor confidence
- Proceeds will support ongoing Phase I clinical trials for HG-CT-1 therapy
- Two patients have already been treated with HG-CT-1
- Additional warrants provided to purchaser could bring in more capital at 270p (50% premium)
- Small fundraising amount may indicate limited financial resources
- Warrant exercise price reset clause could lead to potential future dilution
- Complex share issuance structure needed due to prospectus requirements
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
LONDON, UK / ACCESS Newswire / May 8, 2025 /
Introduction
Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has raised gross proceeds of
The net proceeds of this fundraise will be dedicated to the continuation of the Phase I clinical trials for the Company's Chimeric Antigen Receptor T-cell therapy ("HG-CT-1"), aimed at treating relapsed/refractory acute myeloid leukemia in adults ("R/R AML"). As shareholders will be aware, the first two patients have now been infused with HG-CT-1.
Issuance of the New Ordinary Shares
The Company is currently unable to issue and admit the New Ordinary Shares without either the publication of an FCA approved prospectus or relying upon an exemption to the requirement to issue a prospectus.
Consequentially, this fundraise involves the acceptance by Vladislav Sandler, CEO and director of the Company to subscribe for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article 1(4)(i) and 1(5) (h) of the UK Prospectus Regulation.
Following allotment of the New Ordinary Shares, Vladislav Sandler has agreed to direct their issue to an institution, who will immediately sell these New Ordinary Shares at the same Issue Price to a purchaser identified by it (the "Purchaser").
Warrants
Concurrent with the purchase of the New Ordinary Shares, the Purchaser will receive warrants from the Company on a one-for-one basis. These warrants will be exercisable for a period of 36 months at an exercise price of 270 pence ("Exercise Price"), subject to adjustment in certain circumstances as set out in the warrant instrument including a reset of the Exercise Price if the Company completes a share issuance (or other transaction granting rights to subscribe for equity securities) during the Exercise Period at a price lower than the Exercise Price.
Total Voting Rights
Application will be made for the 250,000 New Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 14 May 2025 ("Admission").
Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 4,343,539.
The above figure of 4,343,539 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
The Company will keep the market informed of future developments as trials proceed.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
"We are pleased to have secured this funding from a single, committed investor on terms that reflect confidence in the long-term value of Hemogenyx. The fact that the raise was completed at the market price, with no discount, sends a clear signal: this investor sees meaningful upside in our share price as we advance HG-CT-1 through clinical development. Their support allows us to maintain momentum in our Phase I trial without diluting value unnecessarily."
UK Market Abuse Regulation (UK MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.
Director's Dealing Notification
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Vladislav Sandler | ||||
2. | Reason for the Notification | |||||
a) | Position/status | PDMR | ||||
b) | Initial notification / Amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Hemogenyx Pharmaceuticals plc | ||||
b) | LEI | 2138008L93GYU5GN6179 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of | ||||
Identification Code | GB00BQVXM815 | |||||
b) | Nature of the transaction | Off Market Allotment | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: Aggregated volume Price | 250,000 Ordinary Shares 180.5 pence per Ordinary Share | ||||
e) | Date of the transaction | 7 May 2025 | ||||
f) | Place of the transaction | London | ||||
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
FAQ
How much did Hemogenyx Pharmaceuticals (HOPHF) raise in their May 2025 placing?
What will Hemogenyx use the proceeds from the May 2025 fundraising for?
What is the status of Hemogenyx's HG-CT-1 clinical trials as of May 2025?
What warrants were issued with Hemogenyx's May 2025 share placing?
How many shares will Hemogenyx have outstanding after the May 2025 placing?
